Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. [electronic resource]

By:

Zhu, Jun

Contributor(s):

He, Wei
Ye, Ming
Fu, Jie
Chu, Yun-Bo
Zhao, Yi-Yang
Zhang, Yan-Jun
Kuo, David
Wu, Bin

Producer: 20190520Description: 2833-2840 p. digitalISSN:

1744-8301

Subject(s):

Afatinib -- economics
Antineoplastic Agents -- economics
Carcinoma, Non-Small-Cell Lung -- drug therapy
Carcinoma, Squamous Cell -- drug therapy
China
Clinical Decision-Making
Cost-Benefit Analysis
Decision Support Techniques
Erlotinib Hydrochloride -- economics
Humans
Lung Neoplasms -- drug therapy
Models, Economic
Progression-Free Survival
Quality-Adjusted Life Years

Online resources:

Available from publisher's website

In: Future oncology (London, England) vol. 14

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Comparative Study; Journal Article

There are no comments on this title.

Browse results Close

Back to results

1 A review of health related quality of life in systemic lupus erythematosus.
by McElhone, K
2 GMDP and psoriasis.
by Bhushan, M
3 Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study.
by McElhone, K
4 Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
by Bhushan, M
5 The effects of low-dose testosterone treatment on lipid metabolism, clotting factors and ultrasonographic ovarian morphology in women.
by Buckler, H M
6 Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being.
by Fortune, D G
7 Lupus-specific health outcome measure for US patients: the LupusQoL-US version.
by Jolly, M
8 The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
by Burden, A D
9 Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.
by Iskandar, I Y K
10 Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study.
by Davison, N J
11 Biaryl diacid inhibitors of human s-PLA2 with anti-inflammatory activity.
by Springer, D M
12 Is the Disease-Specific Lupusqol Sensitive To Changes of Disease Activity In Systemic Lupus Erythematosus Patients After Treatment of A Flare?
by McElhone, K
13 Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
by Iskandar, I Y K
14 A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
by Yiu, Z Z N
15 Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
by Yiu, Z Z N
16 Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
by Iskandar, I Y K
17 Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review.
by Mason, K J

Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung.

APA

Zhu J., He W., Ye M., Fu J., Chu Y., Zhao Y., Zhang Y., Kuo D. & Wu B. (20190520). Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. : Future oncology (London, England).

Chicago

Zhu Jun, He Wei, Ye Ming, Fu Jie, Chu Yun-Bo, Zhao Yi-Yang, Zhang Yan-Jun, Kuo David and Wu Bin. 20190520. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. : Future oncology (London, England).

Harvard

Zhu J., He W., Ye M., Fu J., Chu Y., Zhao Y., Zhang Y., Kuo D. and Wu B. (20190520). Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. : Future oncology (London, England).

MLA

Zhu Jun, He Wei, Ye Ming, Fu Jie, Chu Yun-Bo, Zhao Yi-Yang, Zhang Yan-Jun, Kuo David and Wu Bin. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. : Future oncology (London, England). 20190520.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC